ArticleCurrent microbiology2025
Examination of Genetic Mutations of Clofazimine Resistance in Drug-Resistant Mycobacterium TB Isolates.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-tuberculosis activity and resistance were recently refocused since clofazimine (CFZ) had a significant therapeutic benefit in treating multi-drug resistant tuberculosis (MDR-TB). We investigate the resistance of CFZ and genetic mutations in drug-resistant Mycobacterium tuberculosis strains to enhance the diagnosis and treatment of TB patients. CFZ range of CFZ was determined by testing 20 sensitive strains and 80 MDR clinical isolates. The correlation between the patients' treatment history and CFZ resistance was examined. PCR and DNA sequencing were employed to analyze mutations in the Rv0678, Rv1979c, and pepQ genes of CFZ-resistant and susceptible strains. Drug-resistant M. tuberculosis isolates had an 21.25% incidence of CFZ resistance with MIC > 1 mg/L. Neither bedaquiline nor CFZ therapy was the cause of CFZ resistance. It is necessary to perform a CFZ susceptibility test regardless of prior drug exposure. This study reported novel mutation sites associated with CFZ resistance in the pepQ (V85M/R437L/T438N and G605A/G619M/A610Q), Rv0678 (214 C→Tand 407T→C), and Rv1979c (155 A→C, 562 C→T, 1216G→A,724G→A, and 1057T→G) genes.
Indexed as
Identifiers
41160121What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.